News & Updates

T2D treatment goal shifts from glucose centricity to end-organ protection
T2D treatment goal shifts from glucose centricity to end-organ protection
28 May 2025 byKanas Chan

With the advent of disease-modifying agents such as tirzepatide, the current treatment goal for type 2 diabetes (T2D) extends beyond merely managing glycaemic levels to focusing on a broader approach that emphasizes end-organ protection.

T2D treatment goal shifts from glucose centricity to end-organ protection
28 May 2025
BP medication timing: Bedtime or daytime, the effect’s the same
BP medication timing: Bedtime or daytime, the effect’s the same
27 May 2025 byJairia Dela Cruz

For adults with hypertension being treated in the primary care setting, taking their blood pressure (BP)-lowering medications at bedtime is safe but confers no additional cardiovascular protection as opposed to taking them in the morning, according to the results of the BedMed trial.

BP medication timing: Bedtime or daytime, the effect’s the same
27 May 2025
Antiviral therapy lowers HCC risk in indeterminate CHB phase
Antiviral therapy lowers HCC risk in indeterminate CHB phase
27 May 2025 byStephen Padilla

Patients with chronic hepatitis B (CHB) in the indeterminate phase are predisposed to advanced liver disease and hepatocellular carcinoma (HCC), as shown by a systematic review and meta-analysis.

Antiviral therapy lowers HCC risk in indeterminate CHB phase
27 May 2025